Commission consults on scrutinising drugs passing through EU to check counterfeiting
This article was originally published in SRA
The European Commission is inviting stakeholder feedback on its plans to issue a delegated act concerning a new requirement of the Falsified Medicines Directive under which medicinal products being shipped through the EU for other destinations will have to face additional scrutiny by customs officials or other agencies to ensure they are not counterfeit1.
You may also be interested in...
The EU network of health technology assessment bodies says it is seeing the benefit of systematically involving patients when companies approach it for early scientific advice on evidence generation.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-eight guidance documents have been posted on the tracker since its last update.